Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin Lymphoma (NHL) is a diverse group of blood cancers that start in the lymphocytes (white blood cells). Unlike Hodgkin Lymphoma, NHL is much more common and behaves in a less predictable way, often appearing in multiple lymph node groups simultaneously.

When You Should Consider Non-Hodgkin Lymphoma Evaluation

• Painless swelling of lymph nodes in the neck, armpit, or groin.

• Drenching night sweats.

• Unexplained fever and persistent fatigue.

• Sudden weight loss of more than 10% of body weight.

• Abdominal pain or swelling, which may indicate liver or spleen involvement.

Methods of Non-Hodgkin Lymphoma Classification

• Indolent (Low-grade): Slow-growing types like Follicular Lymphoma that are manageable over many years.

• Aggressive (High-grade): Fast-growing types like Diffuse Large B-cell Lymphoma (DLBCL) that require immediate intensive treatment.

• B-cell Lymphomas: The most common category, accounting for approximately 85% of all cases.

• T-cell Lymphomas: A less common category, making up about 15% of cases.

How Non-Hodgkin Lymphoma Is Managed

• R-CHOP Chemotherapy: The standard regimen for aggressive B-cell lymphomas, combining traditional chemotherapy with the antibody Rituximab.

• Immunotherapy: Use of bispecific antibodies like Polatuzumab or Mosunetuzumab to help the immune system target cancer cells.

• CAR T-cell Therapy: A revolutionary approach for relapsed cases involving the genetic re-engineering of a patient's own T-cells.

• Watch and Wait: Active surveillance used for slow-growing indolent types to monitor the disease before starting intervention.

• Targeted Therapy: Specialized drugs tailored to the specific genetic makeup of the lymphoma subtype.

Pre-Procedure Preparation

• Determining the growth rate (indolent vs. aggressive) to establish the necessary speed of treatment.

• Preparing for a surgical biopsy to ensure a large enough tissue sample for accurate subtyping.

• Baseline cardiac and organ function testing to ensure the patient can tolerate intensive R-CHOP regimens.

• For CAR T-cell therapy, undergoing a process to collect T-cells from the blood for laboratory modification.

Tests Before Non-Hodgkin Lymphoma Treatment

• Excisional Biopsy: The removal of an entire lymph node to definitively identify the specific NHL subtype.

• PET/CT Scan: Advanced imaging to determine the stage (I to IV) based on the location of the cancer relative to the diaphragm.

• Bone Marrow Biopsy: A procedure to check if the lymphoma has spread to the body's blood-producing marrow.

• Molecular Profiling: Testing the cancer cells for specific proteins or genetic markers to guide immunotherapy choices.

Life After Non-Hodgkin Lymphoma Treatment

• The overall 5-year survival rate for NHL is approximately 74%, though this varies by subtype.

• Many patients with aggressive types achieve a total cure if they respond well to initial intensive therapy.

• Indolent lymphoma patients may live for many years, managing the disease as a chronic condition with periodic monitoring.

• Regular follow-up scans and blood work are essential to detect potential recurrence early.

Benefits of Non-Hodgkin Lymphoma Treatment

• Offers a high chance of a total cure for many aggressive high-grade types.

• Effectively manages symptoms and maintains quality of life for those with slow-growing indolent types.

• Provides cutting-edge options like CAR T-cell therapy for patients who have relapsed after standard treatments.

• Utilizes targeted antibodies to increase treatment success while minimizing damage to healthy cells.